scholarly journals In silico identification and in vitro assessment of a potential anticancer peptide sequence retrieved from the Red sea metagenomics library

2018 ◽  
Vol 29 ◽  
pp. iii20
Author(s):  
M.E. Imam ◽  
A. Amleh
2021 ◽  
pp. 129868
Author(s):  
Raviteja Chemboli ◽  
Ravikumar Kapavarapu ◽  
K. Deepti ◽  
K.R.S. Prasad ◽  
Alugubelli Gopi Reddy ◽  
...  

Antibiotics ◽  
2021 ◽  
Vol 10 (4) ◽  
pp. 416
Author(s):  
Sami I. Alzarea ◽  
Abeer H. Elmaidomy ◽  
Hani Saber ◽  
Arafa Musa ◽  
Mohammad M. Al-Sanea ◽  
...  

LC-MS-assisted metabolomic profiling of the Red Sea-derived brown algae Sargassum cinereum “Sargassaceae” dereplicated eleven compounds 1–11. Further phytochemical investigation afforded two new aryl cresol 12–13, along with eight known compounds 14–21. Both new metabolites, along with 19, showed moderate in vitro antiproliferative activity against HepG2, MCF-7, and Caco-2. Pharmacophore-based virtual screening suggested both 5-LOX and 15-LOX as the most probable target linked to their observed antiproliferative activity. The in vitro enzyme assays revealed 12 and 13 were able to inhibit 5-LOX more preferentially than 15-LOX, while 19 showed a convergent inhibitory activity toward both enzymes. Further in-depth in silico investigation revealed the molecular interactions inside both enzymes’ active sites and explained the varying inhibitory activity for 12 and 13 toward 5-LOX and 15-LOX.


2014 ◽  
Vol 27 (5) ◽  
pp. 873-881 ◽  
Author(s):  
Tina Ritschel ◽  
Susanne M. A. Hermans ◽  
Marieke Schreurs ◽  
Jeroen J. M. W. van den Heuvel ◽  
Jan B. Koenderink ◽  
...  

BMC Genomics ◽  
2015 ◽  
Vol 16 (1) ◽  
Author(s):  
Tao Ke ◽  
Huihui Cao ◽  
Junyan Huang ◽  
Fan Hu ◽  
Jin Huang ◽  
...  

2011 ◽  
Vol 17 (12) ◽  
pp. 3063-3073 ◽  
Author(s):  
Amit Nargotra ◽  
Sujata Sharma ◽  
Mohd Iqbal Alam ◽  
Zabeer Ahmed ◽  
Asha Bhagat ◽  
...  

2022 ◽  
pp. 132384
Author(s):  
Aisha ◽  
Muhammad Asam Raza ◽  
Umme Farwa ◽  
Umer Rashid ◽  
Jan K. Maurin ◽  
...  

2018 ◽  
Vol 120 (3) ◽  
pp. 3353-3361 ◽  
Author(s):  
Phongphat Obounchoey ◽  
Lueacha Tabtimmai ◽  
Praphasri Suphakun ◽  
Kannika Thongkhao ◽  
Chatchakorn Eurtivong ◽  
...  

2014 ◽  
Vol 86 (5) ◽  
pp. 593-608 ◽  
Author(s):  
Ashley J. Parks ◽  
Michael P. Pollastri ◽  
Mark E. Hahn ◽  
Elizabeth A. Stanford ◽  
Olga Novikov ◽  
...  

2020 ◽  
Author(s):  
Kumar Sharp

Abstract In this study I have approached through in-silico method or reverse vaccinology taking advantage of the genome sequence of hepatitis G virus. It serves its benefit of identifying antigens seen by both conventional as well as discovering any novel antigen. This peptide candidate can serve a triple purpose of hepatitis C vaccine, hepatitis G vaccine and HIV management addition. 89.2% of the residues were in the favoured region of Ramachandran plot. These points make it favourable for in-vitro trials and further refinement. Because of the high similarity of hepatitis C genome to hepatitis G genome, it is highly probable that this peptide sequence might act as both hepatitis C and hepatitis G vaccine. Patients with past or current HGV infection have higher CD4+ lymphocyte counts and better AIDS-free survival rates. This peptide sequence might cause a breakthrough in the treatment of HIV without exposing them to develop hepatitis.


Sign in / Sign up

Export Citation Format

Share Document